Special Issue "Biosensing and Imaging for Neurodegenerative Diseases"

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: 29 February 2024 | Viewed by 1624

Special Issue Editor

Britton Chance Center for Biomedical Photonics, Huazhong University of Science and Technology, Wuhan, China
Interests: optical imaging of neurotumors: development of diagnostic and therapeutic integrated probes, neural junctions, and neuroimmunoimaging

Special Issue Information

Dear Colleagues,

Accurate diagnoses are crucial in the clinical diagnosis and treatment of neurodegenerative diseases. Increasing evidence has shown that specific biomarkers are helpful for the early detection, prognosis, and efficacy evaluation of neurodegenerative diseases. Highly sensitive sensing technologies (based on biomarkers derived from cerebrospinal fluid, blood, saliva, urine, or tissues and organs) can effectively measure and identify changes in clinically meaningful outcomes. The combination of biosensing with imaging will be more conducive to the accurate diagnosis of diseases and real-time monitoring of treatments. This Special Issue will provide the state of the art of portable sensors and their integration with new imaging methods in the field of neurodegenerative diseases, focusing on the screening of novel biomarkers derived from the periphery (especially blood, saliva, and urine), the exploration of dual-mode biosensors, and new applications of tissue-clearing for 3D imaging and in vivo multimodality imaging techniques.

Prof. Dr. Haiming Luo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • accurate diagnosis
  • biomarkers
  • portable sensors
  • multimodality imaging
  • neurodegenerative diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


15 pages, 2104 KiB  
Elevated Plasma Oligomeric Amyloid β-42 Is Associated with Cognitive Impairments in Cerebral Small Vessel Disease
Biosensors 2023, 13(1), 110; https://doi.org/10.3390/bios13010110 - 07 Jan 2023
Cited by 3 | Viewed by 1164
Due to the heterogeneity of amyloid β-42 (Aβ42) species, the potential correlation between plasma oligomeric Aβ42 (oAβ42) and cognitive impairments in cerebral small vessel disease (CSVD) remains unclear. Herein, a sandwich ELISA for the specific detection of Aβ [...] Read more.
Due to the heterogeneity of amyloid β-42 (Aβ42) species, the potential correlation between plasma oligomeric Aβ42 (oAβ42) and cognitive impairments in cerebral small vessel disease (CSVD) remains unclear. Herein, a sandwich ELISA for the specific detection of Aβ42 oligomers (oAβ42) and total Aβ42 (tAβ42) was developed based on sequence- and conformation-specific antibody pairs for the evaluation of plasma samples from a Chinese CSVD community cohort. After age and gender matching, 3-Tesla magnetic resonance imaging and multidimensional cognitive assessment were conducted in 134 CSVD patients and equal controls. The results showed that plasma tAβ42 and oAβ42 levels were significantly elevated in CSVD patients. By regression analysis, these elevations were correlated with the presence of CSVD and its imaging markers (i.e., white matter hyperintensities). Plasma Aβ42 tests further strengthened the predictive power of vascular risk factors for the presence of CSVD. Relative to tAβ42, oAβ42 showed a closer correlation with memory domains evaluated by neuropsychological tests. In conclusion, this sensitive ELISA protocol facilitated the detection of plasma Aβ42; Aβ42, especially its oligomeric form, can serve as a biosensor for the presence of CSVD and associated cognitive impairments represented by memory domains. Full article
(This article belongs to the Special Issue Biosensing and Imaging for Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop